Trial Profile
A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs CMB 305 (Primary) ; CMB 305 (Primary) ; Cyclophosphamide; G 305; Glycopyranosyl lipid adjuvant; LV 305
- Indications Fallopian tube cancer; Malignant melanoma; Myxoid liposarcoma; Non-small cell lung cancer; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; First in man
- Sponsors Immune Design
- 29 Jun 2020 Status changed from completed to discontinued.
- 21 May 2019 Status changed from active, no longer recruiting to completed.
- 12 Mar 2018 Results published in the Immune Design media release.